Heart failure & cardiomyopathies

Long-Term Impact of Frailty on Outcomes Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy

JACC AdvPublished Propensity-score matched cohort study

Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.40 95% CI 1.26–1.55

Authors' conclusion

Frail patients undergoing ASA for HOCM exhibit higher risks of long-term mortality and adverse clinical outcomes compared with their nonfrail counterparts.

Study context

Population
Patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing alcohol septal ablation (ASA), stratified into frail and nonfrail groups by the Johns Hopkins Adjusted Clinical Group frailty-defining diagnosispatients undergoing ASA, 2,264 (5.8%) were frail, 2,219 patients matched per group
Participants
39,063 patients
Exposure
Frail vs nonfrail patients undergoing ASA
  • Frailn = 2,219
  • Nonfrailn = 2,219reference
Outcome
All-cause mortality
Follow-up
10 years
Methodological detailsUnited States Collaborative Network (2005-2025), Propensity-score matching (1:1)
  • United States Collaborative Network (2005-2025)
  • Propensity-score matching (1:1)

Main finding

All-cause mortality

Hazard ratio

1.40

95% CI 1.26–1.55

P < 0.001

Frail vs Nonfrail
HR 1.40 (95% CI 1.26–1.55); P < 0.001

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)P value
Major adverse cardiac and cerebrovascular event · 1-year post-ASA1.49 (1.30–1.70)P < 0.001
Ischemic stroke · 1-year post-ASA1.57 (1.24–2.00)P < 0.001
Heart failure exacerbation · 1-year post-ASA1.09 (1.01–1.19)P = 0.024
All-cause readmission · 1-year post-ASA1.33 (1.24–1.43)P < 0.001

Acute myocardial infarction, sudden cardiac arrest, antiarrhythmic drugs initiation/escalation, electrical cardioversion

No differences were noted

Safety

OutcomeHR (95% CI)P value
Major bleeding · 1-year post-ASA1.61 (1.38–1.88)P < 0.001

Original publication

Long-Term Impact of Frailty on Outcomes Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. JACC Adv. Published 28 April 2026. doi:10.1016/j.jacadv.2026.102767

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.